SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Allogeneic, CAR-T, CD123, Dual/triple agonist

CB-012's IND Cleared by the FDA; Caribou Joins the AML Race

Here is a brief preview of this blast: On Wednesday, October 18, Caribou announced CB-012's (allogeneic CLL-1 CAR-T; PD-1 KO + B2M KO + TCR KO + B2M-HLA-E KI) IND clearance by the FDA to start a trial in 2-4L AML. Below, Celltelligence provides insights on the trial design while discussing the potential advantages of Caribou's AML program over its competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.